Aim: The present study aimed to explore the antitumor effect and action mechanism of cucurbitacin B (CuB) on human T-cell leukemia Jurkat cells. Methods: Cell proliferation was measured by the MTS assay. Cell cycle distribution, mitochondrial membrane potential and annexin V staining were analyzed using flow cytometry. Western blotting was used to determine the levels of apoptosis- and autophagy-related proteins. Results: CuB inhibited the proliferation of Jurkat cells in a dose-dependent manner and induced G2/M phase arrest as well as formation of tetraploid cells. Accompanied with these effects, the actin dynamics was disrupted, and cofilin, a key regulator of actin dynamics, was persistently activated (dephosphorylated). Although CuB induced around 10% cells undergoing apoptosis, most of the cells were alive after CuB treatment for 24 h. Induction of autophagy was also evident by accumulation of LC3-II. CuB-induced autophagy seemed to be a prosurvival response, since suppression of CuB-induced autophagy significantly increased the activation of caspase-3. Conclusion: Our results demonstrated that CuB exhibited antitumor activity in Jurkat cells through induction of cell cycle arrest and apoptosis which was at least partly due to the disruption of actin dynamics.

Keywords:
Cucurbitacin B, Jurkat cells, Actin dynamics, Cell cycle arrest, Apoptosis, Autophagy
1.
Jayaprakasam B, Seeram NP, Nair MG: Anticancer and antiinflammatory activities of cucurbitacins from Cucurbita andreana. Cancer Lett 2003;189:11–16.
2.
Rebelo Peters R, Baier Krepsky P, Mota SJ: Nitric oxide and cyclooxygenase may participate in the analgesic and anti-inflammatory effect of the cucurbitacins fraction from Wilbrandia ebracteata. Life Sci 2003;73:2185–2197.
3.
Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM: Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003;63:1270–1279.
4.
Wakimoto N, Yin D, O’Kelly J, Haritunians T, Karlan B, Said J, Xing H, Koeffler HP: Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivo. Cancer Sci 2008;99:1793–1797.
5.
Yin D, Wakimoto N, Xing H, Lu D, Huynh T, Wang X, Black KL, Koeffler HP: Cucurbitacin B markedly inhibits growth and rapidly affects the cytoskeleton in glioblastoma multiforme. Int J Cancer 2008;123:1364–1375.
6.
Haritunians T, Gueller S, Zhang L, Badr R, Yin D, Xing H, Fung MC, Koeffler HP: Cucurbitacin B induces differentiation, cell cycle arrest, and actin cytoskeletal alterations in myeloid leukemia cells. Leuk Res 2008;32:1366–1373.
7.
Thoennissen NH, Iwanski GB, Doan NB, Okamoto R, Lin P, Abbassi S, Song JH, Yin D, Toh M, Xie WD: Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res 2009;69:5876–5884.
8.
Liu T, Zhang M, Zhang H, Sun C, Deng Y: Inhibitory effects of cucurbitacin B on laryngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol 2008;265:1225–1232.
9.
Zhang M, Zhang H, Sun C, Shan X, Yang X, Li-Ling J, Deng Y: Targeted constitutive activation of signal transducer and activator of transcription 3 in human hepatocellular carcinoma cells by cucurbitacin B. Cancer Chemother Pharmacol 2009;63:635–642.
10.
Oh H, Mun YJ, Im SJ, Lee SY, Song HJ, Lee HS, Woo WH: Cucurbitacins from Trichosanthes kirilowii as the inhibitory components on tyrosinase activity and melanin synthesis of B16/F10 melanoma cells. Planta Med 2002;68:832–833.
11.
Sun J, Blaskovich MA, Jove R, Livingston SK, Coppola D, Sebti SM: Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene 2005;24:3236–3245.
12.
Chan KT, Li K, Liu SL, Chu KH, Toh M, Xie WD: Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway in leukemia cell line K562. Cancer Lett 2010;289:46–52.
13.
Zhang M, Sun C, Shan X, Yang X, Li-Ling J, Deng Y: Inhibition of pancreatic cancer cell growth by cucurbitacin B through modulation of signal transducer and activator of transcription 3 signaling. Pancreas 2010;39:923–929.
14.
Tannin-Spitz T, Grossman S, Dovrat S, Gottlieb HE, Bergman M: Growth inhibitory activity of cucurbitacin glucosides isolated from Citrullus colocynthis on human breast cancer cells. Biochem Pharmacol 2007;73:56–67.
15.
Graness A, Poli V, Goppelt-Struebe M: STAT3-independent inhibition of lysophosphatidic acid-mediated upregulation of connective tissue growth factor (CTGF) by cucurbitacin I. Biochem Pharmacol 2006;72:32–41.
16.
Nakashima S, Matsuda H, Kurume A, Oda Y, Nakamura S, Yamashita M, Yoshikawa M: Cucurbitacin E as a new inhibitor of cofilin phosphorylation in human leukemia U937 cells. Bioorg Med Chem Lett 2010;20:2994–2997.
17.
Yasuda S, Yogosawa S, Izutani Y, Nakamura Y, Watanabe H, Sakai T: Cucurbitacin B induces G2 arrest and apoptosis via a reactive oxygen species-dependent mechanism in human colon adenocarcinoma SW480 cells. Mol Nutr Food Res 2010;54:559–565.
18.
Ouyang D, Zhang Y, Xu L, Li J, Zha Q, He XH: Histone deacetylase inhibitor valproic acid sensitizes B16F10 melanoma cells to cucurbitacin B treatment. Acta Biochim Biophys Sin 2011;43:487–495.
19.
Liu T, Zhang M, Zhang H, Sun C, Yang X, Deng Y, Ji W: Combined antitumor activity of cucurbitacin B and docetaxel in laryngeal cancer. Eur J Pharmacol 2008;587:78–84.
20.
Chan KT, Meng FY, Li Q, Ho CY, Lam TS, To Y, Lee WH, Li M, Chu KH, Toh M: Cucurbitacin B induces apoptosis and S phase cell cycle arrest in BEL-7402 human hepatocellular carcinoma cells and is effective via oral administration. Cancer Lett 2010;294:118–124.
21.
Iwanski GB, Lee DH, En-Gal S, Doan NB, Castor B, Vogt M, Toh M, Bokemeyer C, Said JW, Thoennissen NH: Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer. Br J Pharmacol 2010;160:998–1007.
22.
Zhang YT, Ouyang DY, Xu LH, Ji Y, Zha QB, Cai J, He XH: Cucurbitacin B induces rapid depletion of the G-actin pool through reactive oxygen species-dependent actin aggregation in melanoma cells. Acta Biochim Biophys Sin 2011;43:556–567.
23.
Chen Q, Ouyang D, Geng M, Xu L, Zhang Y, Wang F, He XH: Valproic acid exhibits biphasic effects on apoptotic cell death of activated lymphocytes through differential modulation of multiple signaling pathways. J Immunotoxicol 2011;8:210–217.
24.
Huang TY, Der Mardirossian C, Bokoch GM: Cofilin phosphatases and regulation of actin dynamics. Curr Opin Cell Biol 2006;18:26–31.
25.
Jang DH, Han JH, Lee SH, Lee YS, Park H, Kim H, Kaang BK: Cofilin expression induces cofilin-actin rod formation and disrupts synaptic structure and function in Aplysia synapses. Proc Natl Acad Sci USA 2005;102:16072–16078.
26.
Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, Iyer S, Smulson M: Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. J Biol Chem 1999;274:22932–22940.
27.
Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T: LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000;19:5720–5728.
28.
Knecht DA, LaFleur RA, Kahsai AW, Argueta CE, Beshir AB, Fenteany G: Cucurbitacin I inhibits cell motility by indirectly interfering with actin dynamics. PLoS One 2010;5:e14039–e14050.
29.
Maloney KN, Fujita M, Eggert US, Schroeder FC, Field CM, Mitchison TJ, Clardy, J: Actin-aggregating cucurbitacins from Physocarpus capitatus. J Nat Prod 2008;71:1927–1929.
30.
Li P, Chua BT, Volbracht C, Tan KO, Li R, Yu VC: Mitochondrial translocation of cofilin is an early step in apoptosis induction. Nat Cell Biol 2003;5:1083–1089.
31.
Ayscough KR, Gourlay CW: The actin cytoskeleton: a key regulator of apoptosis and ageing? Nat Rev Mol Cell Biol 2005;6:583–589.
32.
Zhu B, Fukada K, Zhu H, Kyprianou N: Prohibitin and cofilin are intracellular effectors of transforming growth factor beta signaling in human prostate cancer cells. Cancer Res 2006;66:8640–8646.
33.
Cabado A, Leira F, Vieytes M, Vieites J, Botana L: Cytoskeletal disruption is the key factor that triggers apoptosis in okadaic acid-treated neuroblastoma cells. Arch Toxicol 2004;78:74–85.
34.
Kakkar P, Singh B: Mitochondria: a hub of redox activities and cellular distress control. Mol Cell Biochem 2007;305:235–253.
35.
Chen S, Rehman SK, Wen A, Yao L, Zhang J: Autophagy is a therapeutic target in anticancer drug resistance. Biochim Biophys Acta Rev Cancer 2010;1806:220–229.
36.
Espert L, Denizot M, Grimaldi M, Robert-Hebmann V, Gay B, Varbanov M, Codogno P, Biard-Piechaczyk M: Autophagy is involved in T cell death after binding of HIV-1 envelope proteins to CXCR4. J Clin Invest 2006;116:2161–2172.
37.
Xue L, Fletcher GC, Tolkovsky AM: Autophagy is activated by apoptotic signalling in sympathetic neurons: an alternative mechanism of death execution. Mol Cell Neurosci 1999;14:180–198.
38.
Yu L, Wan F, Dutta S, Welsh S, Liu ZH, Freundt E, Baehrecke EH, Lenardo M: Autophagic programmed cell death by selective catalase degradation. Proc Natl Acad Sci USA 2006;103:4952–4957.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.